sunitinib + bortezomib

Sunitinib + bortezomib is an investigational combination therapy composed of two small molecule drugs with distinct mechanisms of action, evaluated primarily for anticancer activity in solid tumors and hematologic malignancies. Sunitinib is a multi-targeted receptor tyrosine kinase (RTK) inhibitor that blocks signaling pathways involved in tumor growth, angiogenesis, and metastasis by inhibiting targets such as platelet-derived growth factor receptors (PDGFR), vascular endothelial growth factor receptors (VEGFR), KIT, RET, CSF-1R, and FLT3[1]. Bortezomib is a reversible proteasome inhibitor that disrupts the ubiquitin-proteasome pathway by binding to the β5-subunit of the 20S core particle within the 26S proteasome complex. This inhibition leads to cell cycle arrest and apoptosis in malignant cells[5]. The combination has demonstrated synergistic effects in preclinical models and early-phase clinical trials—showing tolerability and preliminary efficacy particularly in thyroid cancer[2][3], melanoma[4], and endometrial carcinoma[6].